Recent Post
VIVA! Communications clinches gold & two silvers at Public Relations Institute of Australia Golden Target Awards
Team VIVA! was dressed to impress at the annual PRIA Golden Target Awards (GTAs) held at the Sofitel Darling Harbour, Sydney, last night (Thursday, December 1, 2022). A show-stopping 146 finalists representing 35 categories assembled for Australia’s longest-running, and most prestigious public relations and communications awards that both celebrate, and recognise, individuals, agencies and campaigns demonstrating strategic…
Read MoreVIVA! Communications clinches Best PR Campaign – Awareness and Advocacy with Edwards Lifesciences at the 2022 PRIME Awards
VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma, and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel. Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…
Read MoreDear Doctor, how’s your blood pressure?
Concerningly, Australian GPs may be inadvertently placing themselves at increased risk of heart attack and stroke, according to new findings from the GP Health Initiative Report released this week, revealing one in seven (14%) GP respondents are not self-monitoring their blood pressure (BP) each year. According to the Servier-commissioned, quantitative, online survey conducted by Metis…
Read MoreCelebrating 21 years of protecting Aussie bones in partnership with Healthy Bones Australia
Yesterday, our team at VIVA! Communications had the privilege of partnering with Healthy Bones Australia to celebrate their 21 years of protecting Aussie bones. We coordinated a national news media announcement to mark this significant milestone, and announced the organisation’s new partnership with an Australian company to develop a breakthrough diagnostic fracture prediction tool. We…
Read More
First treatment in 10 years PBS listed for Aussies
living with aggressive stomach & oesophageal cancers
Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…
Read More